{"entity":{"type":"insider","cik":"0001653052","url":"/insider/0001653052","json_url":"/insider/0001653052.json","name":"Crombez Eric","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":11,"n_filings":10,"first":"2024-03-05","last":"2026-05-15","span_basis":"filed_date"},"name_variants":[{"name":"Crombez Eric","source":"filing","n_filings":10,"first_seen":"2024-03-05","last_seen":"2026-05-15"}],"transactions":[{"id":5813194,"accession":"0001493152-26-023912","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-26-023912","line_url":"/filing/0001493152-26-023912#line-1","is_derivative":false,"issuer_cik":"0000318306","issuer_name":"ABEONA THERAPEUTICS INC.","issuer_ticker":"ABEO","issuer_name_source":null,"issuer_url":"/issuer/0000318306","owner_cik":"0001653052","owner_name":"Crombez Eric","owner_url":"/insider/0001653052","role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26143.0,"shares_display":"26,143","price_per_share":5.5325,"price_display":"5.53","price_state":"stated","total_value":144636.1475,"total_display":"144,636.15","shares_owned_after":37313.0,"shares_owned_after_display":"37,313","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-15","filed_date":"2026-05-15","scope":"insider"},{"id":5745925,"accession":"0001193125-26-208632","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-208632","line_url":"/filing/0001193125-26-208632#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001653052","owner_name":"Crombez Eric","owner_url":"/insider/0001653052","role":"Officer (EVP and Chief Medical Officer)","officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":344.0,"shares_display":"344","price_per_share":24.96,"price_display":"24.96","price_state":"stated","total_value":8586.24,"total_display":"8,586.24","shares_owned_after":111189.0,"shares_owned_after_display":"111,189","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-05","filed_date":"2026-05-06","scope":"insider"},{"id":6072910,"accession":"0001193125-26-089104","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-089104","line_url":"/filing/0001193125-26-089104#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001653052","owner_name":"Crombez Eric","owner_url":"/insider/0001653052","role":"Officer (EVP and Chief Medical Officer)","officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7029.0,"shares_display":"7,029","price_per_share":22.8,"price_display":"22.80","price_state":"stated","total_value":160261.2,"total_display":"160,261.20","shares_owned_after":76301.0,"shares_owned_after_display":"76,301","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-03","scope":"insider"},{"id":5994082,"accession":"0001493152-26-004805","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-26-004805","line_url":"/filing/0001493152-26-004805#line-1","is_derivative":false,"issuer_cik":"0000318306","issuer_name":"ABEONA THERAPEUTICS INC.","issuer_ticker":"ABEO","issuer_name_source":null,"issuer_url":"/issuer/0000318306","owner_cik":"0001653052","owner_name":"Crombez Eric","owner_url":"/insider/0001653052","role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16284.0,"shares_display":"16,284","price_per_share":5.0906,"price_display":"5.09","price_state":"stated","total_value":82895.3304,"total_display":"82,895.33","shares_owned_after":63456.0,"shares_owned_after_display":"63,456","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-02","filed_date":"2026-02-02","scope":"insider"},{"id":4603248,"accession":"0001641172-25-024384","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001641172-25-024384","line_url":"/filing/0001641172-25-024384#line-1","is_derivative":false,"issuer_cik":"0000318306","issuer_name":"ABEONA THERAPEUTICS INC.","issuer_ticker":"ABEO","issuer_name_source":null,"issuer_url":"/issuer/0000318306","owner_cik":"0001653052","owner_name":"Crombez Eric","owner_url":"/insider/0001653052","role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4718.0,"shares_display":"4,718","price_per_share":6.9273,"price_display":"6.93","price_state":"stated","total_value":32683.0014,"total_display":"32,683.00","shares_owned_after":42427.0,"shares_owned_after_display":"42,427","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-14","filed_date":"2025-08-15","scope":"insider"},{"id":4496033,"accession":"0000950170-25-063792","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-063792","line_url":"/filing/0000950170-25-063792#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001653052","owner_name":"Crombez Eric","owner_url":"/insider/0001653052","role":"Officer (EVP and Chief Medical Officer)","officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":520.0,"shares_display":"520","price_per_share":39.24,"price_display":"39.24","price_state":"stated","total_value":20404.8,"total_display":"20,404.80","shares_owned_after":71530.0,"shares_owned_after_display":"71,530","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-05","filed_date":"2025-05-05","scope":"insider"},{"id":4496028,"accession":"0000950170-25-063792","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-063792","line_url":"/filing/0000950170-25-063792#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001653052","owner_name":"Crombez Eric","owner_url":"/insider/0001653052","role":"Officer (EVP and Chief Medical Officer)","officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":242.0,"shares_display":"242","price_per_share":35.11,"price_display":"35.11","price_state":"stated","total_value":8496.62,"total_display":"8,496.62","shares_owned_after":71680.0,"shares_owned_after_display":"71,680","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-21","filed_date":"2025-05-05","scope":"insider"},{"id":4495098,"accession":"0000950170-25-032794","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-032794","line_url":"/filing/0000950170-25-032794#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001653052","owner_name":"Crombez Eric","owner_url":"/insider/0001653052","role":"Officer (EVP and Chief Medical Officer)","officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8945.0,"shares_display":"8,945","price_per_share":42.1,"price_display":"42.10","price_state":"stated","total_value":376584.5,"total_display":"376,584.50","shares_owned_after":71922.0,"shares_owned_after_display":"71,922","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-03","filed_date":"2025-03-04","scope":"insider"},{"id":3151765,"accession":"0000950170-24-052788","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-052788","line_url":"/filing/0000950170-24-052788#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001653052","owner_name":"Crombez Eric","owner_url":"/insider/0001653052","role":"Officer (EVP and Chief Medical Officer)","officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":354.0,"shares_display":"354","price_per_share":43.66,"price_display":"43.66","price_state":"stated","total_value":15455.64,"total_display":"15,455.64","shares_owned_after":48431.0,"shares_owned_after_display":"48,431","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-02","filed_date":"2024-05-03","scope":"insider"},{"id":3214522,"accession":"0000950170-24-046055","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-046055","line_url":"/filing/0000950170-24-046055#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001653052","owner_name":"Crombez Eric","owner_url":"/insider/0001653052","role":"Officer (EVP and Chief Medical Officer)","officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":142.0,"shares_display":"142","price_per_share":44.1,"price_display":"44.10","price_state":"stated","total_value":6262.2,"total_display":"6,262.20","shares_owned_after":48785.0,"shares_owned_after_display":"48,785","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-18","filed_date":"2024-04-19","scope":"insider"},{"id":2674630,"accession":"0000950170-24-026635","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-026635","line_url":"/filing/0000950170-24-026635#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001653052","owner_name":"Crombez Eric","owner_url":"/insider/0001653052","role":"Officer (EVP and Chief Medical Officer)","officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1238.0,"shares_display":"1,238","price_per_share":53.76,"price_display":"53.76","price_state":"stated","total_value":66554.88,"total_display":"66,554.88","shares_owned_after":48927.0,"shares_owned_after_display":"48,927","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-01","filed_date":"2024-03-05","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":11,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":11,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":11},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000318306","name":"ABEONA THERAPEUTICS INC.","url":"/issuer/0000318306","role":"Director","n_filings":3,"first_seen":"2025-08-15","last_seen":"2026-05-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001515673","name":"Ultragenyx Pharmaceutical Inc.","url":"/issuer/0001515673","role":"Officer (EVP and Chief Medical Officer)","n_filings":7,"first_seen":"2024-03-05","last_seen":"2026-05-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001653052","retrieved_at":"2026-08-21T07:08:30+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}